Skip to content

News
Careers
Contact

Asia Pacific
Australia
Europe
United States
Brazil
Latin America

Search

Sirtex

Region
Asia Pacific

Australia

Europe

United States

Brazil

Latin America
Search

Professionals
Professionals

Specialties

SUMM⁹⁰YT

SIR-Spheres^®
Read More...

Ordering SIR-Spheres^®
Read More...
Patients
Patients

About Liver Cancer

SIR-Spheres^® Y-90 Resin Microspheres

Resources

Frequently Asked Questions

Contact us

Patient Support
Read More...

Frequently Asked Questions
Read More...
Products
Products

SIR-Spheres^® Y-90 Resin Microspheres

SIROS^TM

EmboCept^®S DSM 50 μm

INSYTE with SurePlan^TM LiverY90

Product Ordering

EmboCept^®S DSM 50 μm
Read More...

SIR-Spheres^®
Read More...
About Sirtex
About Sirtex

Mission and Values

Leadership Team

Grant Programs

Careers

Locations

Global Career Opportunities
Read More...

Mission and Values
Read More...

News
Careers
Contact

Region
Australia

Asia Pacific

Europe

United States

Brazil

Latin America

SIROS^TM

Products
SIR-Spheres
SIROS

Resources

download

SIROS Info Sheet

download

SIROS Activity Preparation Poster

SIROS Delivery System Set-up

SIROS Administration Set-up

SIROS - SIR-Spheres Activity Preparation

SIR-Spheres^®
EmboCept^® S DSM 50 μm

Return to top of page

Advancing to the next level.

Connect with Sirtex

LinkedIn
Twitter

Data Protection
Sitemap
Terms of Use
Impressum

Global settings

Region

SIR-Spheres® Y-90 resin microspheres are a medical device used in selective internal radiation therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

SIR-Spheres^® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

EmboCept is a registered trademark of Magle PharmaCept GmbH. Magle PharmaCept GmbH is part of Magle Group.

APM-EMEA-005-03-21 V2

Compte-tenu de la règlementation en France, le contenu de ce site n’est pas accessible sur le territoire français.
En cliquant « Oui / Yes », vous confirmez que vous n’accédez pas ce site du territoire français.
En cliquant sur « Quitter / Exit », vous serez dirigé vers un autre site web.

Due to regulations in France, the content of this website can only be accessed from outside the French territory.
By clicking « Oui / Yes » you are confirming that you are not accessing the site from the French territory.
By clicking on « Quitter / Exit », you will be directed away from this site.

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

This content is intended for journalists only

By clicking "Continue" you are confirming that you are a journalist. If you are not a journalist, then please click on Sirtex logo which will direct you to the Sirtex homepage.

Now leaving sirtex.com

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Effective May 7, 2021

SIR-Spheres will have the following indication for use:

SIR-Spheres Y 90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Effective May 7, 2021

SIR-Spheres will have the following indication for use:

SIR-Spheres Y 90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

.

This content is intended for Healthcare Professionals only

By clicking “Continue” you are confirming that you are a Healthcare Professional. If you are not a Healthcare Professional, please click on Sirtex logo which will direct you to the Sirtex homepage.